Manhattan Pharmaceuticals (Manhattan) has provided update on ongoing development program for Hedrin. Hedrin is a next generation, non-pesticide treatment for Pediculosis (head lice). The drug is currently being developed as a 1-hour head lice treatment by and through a joint-venture with Nordic.
The joint venture has requested a meeting with FDA to confirm whether a study is necessary, and to determine the trial design and patients requirement. The joint venture would initiate clinical study shortly after receiving FDA feedback.
Manhattan, on behalf of the joint venture, is looking to secure commercialization and marketing partner for Hedrin, and discussions are currently on with potential partners for both the US and Canada.
Hedrin is currently marketed in 27 countries, including UK and France.